MedTrace Logo

Relative Bioavailability Study for GSK1278863A

NCT01319006 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-06-26

No results posted yet for this study

Summary

A randomized, open-label, 3-period crossover study.

Conditions

  • Anaemia

Interventions

DRUG

GSK1278863A

100mg (x90=13um), oral tablet, single-dose with 7 day wash-out

DRUG

GSK1278863A

100mg (x90=29um), oral tablet, single-dose with 7 day wash-out

DRUG

GSK1278863A

100mg (x90=41um), oral tablet, single-dose with 7 day wash-out

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-25
Primary Completion
2011-04-18
Completion
2011-04-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01319006 on ClinicalTrials.gov